The ultra-high performance liquid chromatography coupled with tandem mass spectrometry metabolomics was used to explore the therapeutic mechanisms of schisandrol A against pulmonary fibrosis and revealed that TGF-β1-VIM-carnosine and TGF-β1-ID3-creatine pathway were key pathways of Sch A modulating the metabolic disorders [137]. The gene discussed is TGFB1; the disease is pulmonary fibrosis.